Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma
- Carmina Muñoz Bastidas 1, Mario Tapia Tapia 2, Andrés Calva López 2, Vanessa Talavera Cobo 2, Juan Colombas Vives 2, Eduardo Miraval Wong 3, Cristina Gutiérrez Castané 2, Francisco Javier Ancizu Marckert 2, Marcos Torres Roca 2, Luis Labairu Huerta 2, Fernando Diez-Caballero Alonso 2, José Enrique Robles García 2, Felipe Villacampa Aubá 2, Daniel González Padilla 4, Bernardino Miñana López 4, Daniel Sánchez Zalabardo 2
- 1University of Navarra Clinic, Urology, Pamplona, Spain. cmunozbasti@unav.es.
- 2University of Navarra Clinic, Urology, Pamplona, Spain.
- 3University of Navarra Clinic, Pathology, Pamplona, Spain.
- 4University of Navarra Clinic, Urology, Madrid, Spain.
- 0University of Navarra Clinic, Urology, Pamplona, Spain. cmunozbasti@unav.es.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.TFE3 rearrangement in renal cell carcinoma (RCC) is linked to higher recurrence and shorter progression-free survival (PFS). Fluorescence in situ hybridization (FISH) is crucial for accurate diagnosis, as immunohistochemistry (IHC) has low specificity.
Area Of Science
- Oncology
- Molecular Pathology
- Genitourinary Pathology
Background
- Renal cell carcinoma (RCC) encompasses diverse subtypes with varying prognoses.
- TFE3 rearrangements are found in a subset of RCCs, but their clinical impact requires further elucidation.
- Immunohistochemistry (IHC) is often used for initial screening, but its diagnostic accuracy for TFE3 rearrangement needs validation.
Purpose Of The Study
- To investigate the prognostic significance of TFE3 rearrangement in renal cell carcinoma (RCC).
- To analyze clinicopathological features associated with RCC recurrence in TFE3-rearranged tumors.
- To evaluate the diagnostic utility of immunohistochemistry (IHC) for TFE3 rearrangement and its correlation with outcomes.
Main Methods
- Screening of clear cell RCC (ccRCC) patients.
- Immunohistochemistry (IHC) for TFE3 expression.
- Fluorescence in situ hybridization (FISH) to confirm TFE3 rearrangement in IHC-positive cases.
- Collection and analysis of clinicopathological and survival data.
Main Results
- TFE3 rearrangement was confirmed in 1.15% of RCC cases via FISH.
- TFE3-rearranged RCC patients were younger and exhibited a significantly higher recurrence rate (50%) compared to ccRCC (18.8%).
- TFE3 rearrangement, tumor size, and metastasis were independent prognostic factors for recurrence; PFS was significantly shorter in TFE3-rearranged RCC.
Conclusions
- TFE3 rearrangement is an independent prognostic factor for RCC recurrence and worse progression-free survival (PFS).
- Fluorescence in situ hybridization (FISH) is essential for confirming TFE3 rearrangement due to the low specificity of IHC.
- Close follow-up is recommended for patients with TFE3-rearranged RCC.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

